Mehmet Toner,
Helen Andrus Benedict Professor of Biomedical Engineering,
Massachusetts General Hospital (MGH), Harvard Medical School, and Harvard-MIT Division of Health Sciences and Technology
Mehmet Toner is the Helen Andrus Benedict Professor of Biomedical Engineering at the Massachusetts General Hospital (MGH), Harvard Medical School, and Harvard-MIT Division of Health Sciences and Technology. Mehmet received a BS degree from Istanbul Technical University and an MS degree from the Massachusetts Institute of Technology (MIT), both in Mechanical Engineering. Subsequently he completed his PhD degree in Medical Engineering at Harvard-MIT Division of Health Sciences and Technology in 1989. Mehmet is the co-founding Director of the Center for Engineering in Medicine, and BioMicroElectroMechanical Systems Resource Center (BMRC) at the MGH. He is also the Director of Research at the Shriners Hospital for Children Boston. Mehmet holds over 50 patents, has more than 350 publications, and is a co-founder of multiple biotechnology start-ups. Mehmet is a “Fellow of the American Institute of Medical and Biological Engineering”, “Fellow of the American Society of Mechanical Engineers”, and “Fellow of the Society for Cryobiology.” In 2012, he was given the “Luyet Medal” by the Society for Cryobiology. In 2013, he received the “H.R. Lissner Medal” from the American Society of Mechanical Engineering. He is a member of the “National Academy of Inventors” and a member of the “National Academy of Engineering.”
Microfluidics to Isolate Single and Clusters of Rare Circulating Tumor Cells to Manage Cancer Patients
Thursday, 16 March 2017 at 10:00
Add to Calendar ▼2017-03-16 10:00:002017-03-16 11:00:00Europe/LondonMicrofluidics to Isolate Single and Clusters of Rare Circulating Tumor Cells to Manage Cancer PatientsSELECTBIOenquiries@selectbiosciences.com
Viable tumor-derived circulating tumor cells (CTCs) have been identified in peripheral blood from cancer patients and are not only the origin of intractable metastatic disease but also marker for early cancer. However, the ability to isolate CTCs has proven to be difficult due to the exceedingly low frequency of CTCs in circulation. As a result their clinical use until recently has been limited to prognosis with limited clinical utility. More recently, we introduced several microfluidic methods to improve the sensitivity of rare event CTC isolation, a strategy that is particularly attractive because it can lead to efficient purification of viable CTCs from unprocessed whole blood. The micropost CTC-Chip (µpCTC-Chip) relies on laminar flow of blood cells through anti-EpCAM antibody-coated microposts, whereas the herringbone CTC-Chip (HbCTC-Chip) uses micro-vortices generated by herringbone-shaped grooves to efficiently direct cells toward antibody-coated surfaces. These antigen-dependent CTC isolation approaches, also called “positive selection”, led to the development of a third technology, which is tumor marker free (or antigen-independent) sorting of CTCs. We call this integrated microfluidic system the CTC-iChip, based on the inertial focusing strategy, which allows positioning of cells in a near-single file line, such that they can be precisely deflected using minimal magnetic force.
Add to Calendar ▼2017-03-16 00:00:002017-03-17 00:00:00Europe/LondonBioMEMS, Microfluidics and Biofabrication: Technologies and ApplicationsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2017-03-16 10:00:002017-03-16 11:00:00Europe/LondonMicrofluidics to Isolate Single and Clusters of Rare Circulating Tumor Cells to Manage Cancer PatientsSELECTBIOenquiries@selectbiosciences.com
 2_150x75.png)
